The archive · Bio & Materials · Financial decision · 2019–2021
Loyal: solo founder's $5.1M seed for dog-longevity drugs
Loyal develops drugs to extend dog lifespan; founder Celine Halioua raised a $5.1M seed on an idea and deck before hiring a team or doing the science.
Loyal
What the business is
Loyal is a biotech company developing drugs to extend dog lifespan and healthspan, an early bet in what its founder calls consumer bio: drug discovery aimed at pet owners who pay out of pocket.
Starting capital：$5.1M seed (closed January 2020); ~$6M more by May 2021
How it started
Celine Halioua, a neuroscience graduate, former Oxford PhD candidate and two-year VC, was not planning to start a company when a campfire conversation about making dogs live longer reached Greg Rosen, an investor building a pet-genomics thesis. Regular coffees through summer 2019 turned the idea into Loyal (raised under the name Celevity); when Rosen offered a term sheet, she decided to leave her job and go out for her first round.
What happened
She raised for an idea and a deck — no co-founder, team or lab data — targeting Silicon Valley and NYC tech and biotech funds while skipping traditional East Coast biotech VCs, whose pre-lead drug deals she considered far more dilutive. After Rosen and Longevity Fund committed about half the round on terms they set together, she ran a CRM of 157 investors, compressed about 65 pitch meetings into six weeks, and 17 investors (roughly 11%) converted; the first 80% of the round subscribed in about two weeks, the last 20% took three, and the round closed oversubscribed at $5.1M in January 2020. She deliberately prioritized speed and partner fit over dilution, iterating an 80-page deck into a ~20-slide main story with a detailed appendix, and later closed roughly another $6M.
No ending yet — it is still running.
Background
Loyal is a biotech company developing drugs to extend dog lifespan and healthspan — its founder places it in an 'incipient consumer bio' category, drug discovery aimed at pet owners who pay out of pocket. In January 2020, founder Celine Halioua closed a $5.1M seed round, her first financing for her first company, for what she describes as 'an idea and deck': no co-founder, no team, and no science discovered yet.
The round began by serendipity: a campfire chat about making dogs live longer reached Greg Rosen, an investor with a pet-genomics thesis, who offered a term sheet after a summer of conversations. Halioua — a former Oxford PhD candidate with two years of VC experience — targeted Silicon Valley and NYC tech and biotech funds, skipping East Coast biotech VCs. She built a CRM of 157 investors, pitched 65 in six weeks, and 17 (roughly 11%) invested; the first 80% of the round took two weeks, the last 20% three, and it closed oversubscribed, priced for speed and partner fit over dilution.
By the time she published the postmortem in May 2021 she had closed another ~$6M, and her account of raising as a first-time, female, solo founder drew 284 points and 234 comments on Hacker News. The thread debated the case's core bet — whether dog longevity is a 'moonshot' science company or simply a market tech VCs could love — with several commenters crediting her network, credentials and founder-market fit for making an idea-and-deck raise credible.
What has to be true
- Biotech VCs doubted the pet market could support a $1B+ company; tech VCs loved the market but needed time on the science — the cap table ended up mostly tech.
- Compressed timelines manufactured urgency: 65 conversations inside about six weeks produced fast yes/no's and stopped the deal dying of time, though it cost investors who wanted a longer courtship.
- She traded dilution for capital velocity deliberately: in biotech, money in the coffers correlates with success, and solo-founder flexibility let her oversubscribe on terms she liked.
- Founder-market fit substituted for team and data: domain expertise, an Oxford PhD background, a VC network and a longevity community made an idea-and-deck raise credible to 17 investors.
What can be applied
Fundraising is engineerable even from an outsider starting point: CRM the market, compress the timeline, iterate the pitch — and deliberately trade dilution for speed and partner fit.
Aftermath
As of 2021-05-27, Loyal (raised under the name Celevity) had closed roughly $11M in total — the $5.1M January 2020 seed plus about $6M more — and was developing drugs against a specific protein intended to extend dog lifespan and healthspan, with no product or revenue yet disclosed. The founder's essay, written to document the playbook for founders 'who do not fit the pattern', was the company's main public artifact and reached the Hacker News front page on the day it was submitted.
Sources
- How I raised a $5.1M seed as a first-time, female, solo founder for a biotech moonshot
- How I raised a $5.1M seed as a first-time, female, solo founder for a biotech co
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card